Abstract: The present invention relates to inhibiting proliferation and inducing apoptosis in activated lymphocytes, including T cells and B cells. The invention also provides compositions and methods for inhibiting proliferation and inducing apoptosis in activated lymphocytes, as well methods for treating diseases associated with activated lymphocytes by administering 5-HT receptor antagonists.
Type:
Grant
Filed:
August 31, 2007
Date of Patent:
July 19, 2011
Assignee:
Immune Control Inc.
Inventors:
Stephen Roth, Clayton Buck, Christopher Self, Gary Olson
Abstract: The present invention provides a device of integrated neuronal cells interfaced with an electronic device and a method of producing the same.
Type:
Grant
Filed:
August 20, 2008
Date of Patent:
July 5, 2011
Assignee:
The Trustees of the University of Pennsylvania
Inventors:
Douglas H. Smith, Bryan Pfister, David F. Meaney
Abstract: The present invention relates to a kit for diagnosing a disorder comprising a reagent that detects FGF23 polypeptides and mutant FGF23 polypeptides.
Type:
Grant
Filed:
November 7, 2007
Date of Patent:
May 24, 2011
Assignees:
Advanced Research & Technology Institute, Ludwig-Maximilians-Universitat Munchen Abeteilung Mediziniche Genetik
Inventors:
Michael Econs, Ken White, Tim Matthias Strom, Thomas Meitinger
Abstract: The invention relates to novel nucleic acids encoding a mammalian PCADM-1 gene, and proteins encoded thereby, whose expression is increased in certain diseases, disorders, or conditions, including, but not limited to, prostate cancer. The invention further relates to methods of detecting and treating prostate cancer, comprising modulating or detecting PCADM-1 expression and/or production and activity of PCADM-1 polypeptide. Further, the invention relates to novel assays for the identification of DNA-binding proteins and the double-stranded oligonucleotide sequences that specifically bind with them. Finally, the invention relates to DNAZYMs or DNA enzymes which specifically bind PCADM-1 mRNA to inhibit PCADM-1 gene expression and thereby destroy tumor cells and tumor tissue.
Type:
Grant
Filed:
May 18, 2010
Date of Patent:
May 10, 2011
Assignee:
Philadelphia Health and Education Corporation
Abstract: The invention provides an immunogenic composition comprising MSPk-8 linked to an antigen. Methods of using the composition to induce an immune response in an animal are also provided.
Type:
Grant
Filed:
February 21, 2008
Date of Patent:
April 26, 2011
Assignee:
Philadelphia Health Education Corporation
Abstract: The present invention relates to inhibiting proliferation and inducing apoptosis in activated lymphocytes, including T cells and B cells. The invention also provides compositions and methods for inhibiting proliferation and inducing apoptosis in activated lymphocytes, as well methods for treating diseases associated with activated lymphocytes by administering 5-HT receptor antagonists.
Type:
Grant
Filed:
August 31, 2007
Date of Patent:
April 12, 2011
Assignee:
Immune Control, Inc.
Inventors:
Stephen Roth, Clayton Buck, Christopher Self, Gary Olson
Abstract: Methods for producing echogenic polymer microcapsules and nanocapsules for use in diagnostic imaging and delivery of bioactive compounds as well as targeted imaging and delivery to selected tissues and cells are provided. Compositions containing these echogenic polymer microcapsules and nanocapsules for use in diagnostic imaging and delivery of bioactive agents are also provided.
Abstract: The present invention relates to new NOS variants or mutants which contain structural alterations in the site of Akt dependent phosphorylation. The altered NOS proteins or peptides, especially the human eNOS proteins or peptides, Akt proteins or polypeptides and their encoding nucleic acid molecules are useful as gene therapy agents for the treatment of diseases including post angioplasty restenosis, hypertension, atherosclerosis, heart failure, diabetes and diseases with defective angiogenesis. NOS proteins and peptides are also useful in methods of screening for agents which modulate NOS activity.
Abstract: An integrated payment system directed to the care of a subject and method of same is described herein. This system and method includes a care planner for accurately approximating the costs for the subject during the course of care, an insurance verifier and estimator that identifies the portion of the costs for the subject that is covered by the subjects insurance, wherein the approximated costs less the covered insurance leaves a subject payment, a discount planner that evaluates the application of at least one discount to the subject payment, and a payment planner that enables a payment arrangement for the subject for the subject payment less any applied discounts.
Abstract: A process for growth of boron-based nanostructures, such as nanotubes and nanowires, with a controlled diameter and with controlled chemical (such as composition, doping) as well as physical (such as electrical and superconducting) properties is described. The boron nanostructures are grown on a metal-substituted MCM-41 template with pores having a uniform pore diameter of less than approximately 4 nm, and can be doped with a Group Ia or Group IIa electron donor element during or after growth of the nanostructure. Preliminary data based on magnetic susceptibility measurements suggest that Mg-doped boron nanotubes have a superconducting transition temperature on the order of 100 K.
Abstract: The instant invention is drawn to a hepatocyte targeted composition comprising a mixture of free glargine insulin and glargine insulin associated with a water insoluble target molecule complex, wherein the complex comprises multiple linked individual units and a supra-molecular lipid construct matrix. Glargine insulin is present within the complex in at least one form wherein the glargine insulin has a positive charge which interacts with a negative charge on the complex. The invention also includes methods for the manufacture of the composition and methods of managing blood glucose levels in individuals with Type I and Type II diabetes.
Abstract: The present invention provides biocompatible vesicles comprising semi-permeable, thin-walled encapsulating membranes which are formed in an aqueous solution, and which comprise one or more synthetic super-amphiphilic molecules. When at least one super-amphiphile molecule is a block copolymer, the resulting synthetic vesicle is termed a “polymersome.” The synthetic, reactive nature of the amphiphilic composition enables extensive, covalent cross-linking of the membrane, while maintaining semi-permeability. Cross-linking of the polymer building-block components provides mechanical control and long-term stability to the vesicle, thereby also providing a means of controlling the encapsulation or release of materials from the vesicle by modifying the composition of the membrane. Thus, the encapsulating membranes of the present invention are particularly suited for the reliable, durable and controlled transport, delivery and storage of materials.
Type:
Grant
Filed:
February 20, 2007
Date of Patent:
January 11, 2011
Assignees:
The Trustees of the University of Pennsylvania, Regents of the University of Minnesota
Inventors:
Dennis E. Discher, Bohdana M. Discher, You-Yeon Won, James C-M Lee, Daniel A. Hammer, Frank Bates
Abstract: The instant invention is drawn to a hepatocyte targeted composition comprising a mixture of free recombinant human insulin isophane and free Recombinant human regular insulin insulin and a mixture of recombinant human insulin isophane and Recombinant human regular insulin insulin associated with a water insoluble target molecule complex, wherein the complex comprises multiple linked individual units and a supra-molecular lipid construct matrix. Recombinant human insulin isophane and Recombinant human regular insulin insulin are present within the complex in at least one form wherein the recombinant human insulin isophane and Recombinant human regular insulin insulin have regions of positive charge which interacts with a negative charge on the complex. The invention also includes methods for the manufacture of the composition and methods of managing blood glucose levels in individuals with Type I and Type II diabetes.